SHORLA PHARMA RECEiVES FDA FILING ACCEPTANCE AND PRIORITY REVIEW FOR SH-111, ITS T-CELL LEUKEMIA TREATMENT

Shorla Pharma have submitted, and the US Food and Drug Administration (‘FDA’) have accepted for filing, its application for its SH-111 oncology drug designed to treat T-cell leukemia. SH-111 is a lifesaving treatment that is often in shortage and the company looks forward to working closely with FDA to bring this much needed product to market later this year.

Read more at: https://www.businesswire.com/news/home/20210423005122/en/Shorla-Pharma-Announces-FDA-Filing-Acceptance-and-Priority-Review-for-T-cell-Leukemia-Treatment

TARGETING AN UNMET NEED

Our goal is to bring to market a product that represents a new standard of treatment in particular for children with T-ALL.

Manufacturing

The manufacture of SH-111, a sterile oncology product is via state of the art robotic filling technology at our GMP partner facility. Please see video below.